Its roles Owner Offtaker
Sanofi is a global biopharmaceutical company headquartered in Paris, France. It researches, develops, manufactures, and supplies prescription medicines and vaccines. The company’s R&D and product portfolio span immunology, oncology, rare diseases, neurology, and diabetes, with vaccines activities organized under Sanofi Pasteur and specialty care historically associated with Sanofi Genzyme.
From a manufacturing and process perspective, Sanofi operates an extensive industrial network that produces biologics (including monoclonal antibodies), recombinant proteins, insulin and other therapies, as well as selected small-molecule medicines. Capabilities include cell culture and microbial fermentation, downstream purification, and sterile fill-finish at clinical and commercial scales, supported by GMP quality control and global supply chain operations. Major production and development hubs are located across Europe, North America, and Asia.
chemXplore tracks 5 projects involving Sanofi, of which 2 are active.
Besides these 2, the record holds 3 completed projects.
Closest to start-up first.
1 more active project and the 3 that are completed, on hold or cancelled are in the record. See all 5 in chemXplore →
Funds will build the Advanced Thorium Extraction Facility to scale thorium‑228 supply for lead‑212 targeted alpha therapies and feed ATLabs.
Merck forms Oncology and Specialty units, appoints new leaders, and aims to boost commercial success and pipeline execution.
Continuous-flow, lower-footprint paracetamol process; 15,000 t/yr from end‑2026; backed by France 2030 with UPSA and Opella as partners.
The new unit, supported by France Relance, will produce 10,000 tonnes of paracetamol annually by 2023, using innovative, eco-friendly processes to meet growing demand and enhance EU health sovereignty.
€300M investment will expand production capabilities, add new labs, and increase floor space by 8000 m². The site will support a pipeline of biologics, including monoclonal antibodies.
Investing €200M, the company will build a fully automated cold warehouse and a multi-purpose building for medical tech, creating 500 jobs and expanding insulin production capabilities.
The new plant, costing EUR 30 million, will produce monoclonal antibodies for trials, doubling production capacity and enhancing the company's biopharmaceutical focus and market position.
What each is building and closing, and the pipelines and grids between them, on one map.
